properties of the cyclin dependent kinase inhibitor
CYC202 (R-roscovitine). Int. J. Cancer, 102(5),
463-468 (2002).
8. Wartenberg, M., et al., Modulation of intrinsic P-
glycoprotein expression in multicellular
Narahashi, Y., J. Biochem.,
46(5), 653-667 (1959).
10. Nomoto, M. et al., J. Biochem., 48(3), 453-463
(1960).
11. Nomoto, M. et al., J. Biochem., 48(4), 906-918
(1960).
12.
permeability transition: a
common pathway to necrosis and apoptosis. Biochem.
Biophys. Res. Commun 304 (3), 463–470 (2003).
69. Wilkening S et al. Comparison of primary human
hepatocytes and hepatoma cell line
. Supplementary Information
y Version: 09 DNA Isolation Kit for Cells and Tissues
09
17
.0
49
60
06
80
01
9
6. Supplementary Information
6.1. Conventions
To make information consistent
Vassar, R., and Citron, M. 2000. Neuron 27, 419.
Zhang, Z., et al. 2000. Nat. Cell Biol. 2, 463.
Haass, C., and De Stooper, B. 1999. Science 286,
916.
Sinha, S., and Lieberburg, I. 1999. Proc
activity. Purity:
≥98% by HPLC. M.W. 614.6.
Ref.: Kau, T.R., et al. 2003. Cancer Cell 4, 463.
Akt Inhibitor IV in Solution
A ready-to-use 10 mM (1 mg/163 µl) solution of Akt
activity. Purity:
≥98% by HPLC. M.W. 614.6.
Ref.: Kau, T.R., et al. 2003. Cancer Cell 4, 463.
Akt Inhibitor IV in Solution
A ready-to-use 10 mM (1 mg/163 µl) solution of Akt
downstream
of PI3K. Purity: ≥98% by HPLC. M.W. 614.6.
Ref.: Kau, T.R., et al. 2003. Cancer Cell 4, 463.
Protein yields obtained after processing samples with common precipitation
methods. Protein at
Area
Alternate
Unit Area
(for highly
contaminated
sample)Measuring
Eyepiece
Scale
0
20
Figure 49. Placing aerosol adapter into rubber stopper, hose end down.
Filter
Membrane
Support
H4 (Lys20) H, M, Vrt WB, IC, PIA, ChIP Sera Rabbit 200 µL 07-463
TrkA R WB, IH, IP Pur Rabbit 100 µg AB1577
Troponin I, aa 41-49, clone 284 (19C7) H, M, R, B,
Stiehler, M. Culture media for the
differentiation of mesenchymal stromal cells. Acta Bio-
mater 7, 463, 2011.
32. Canalis, E., Economides, A.N., and Gazzerro, E. Bone
morphogenetic proteins, their antagonists
Res. 64, 4394.
Bain, J. et al. 2003. Biochem J. 371, 199-204.
Kau, T.R., et al. 2003. Cancer Cell 4, 463.
Kozikowski, A.P., et al. 2003. J. Am. Chem. Soc.125, 1144.
Davies, S.P., et al. 2000. Biochem J. 351
461 α-MSH M0939 5443 POMC NP_001030333.1 P y n/d n/d
462 MSH6 M2445 2956 MSH6 NP_000170.1 P y y y
463 MSH6 M2820 2956 MSH6 NP_000170.1 P y y n/d
464 MSK-1 M5437 445349, 9252 RPS6KA5,Rps6ka5 ,NP_872198.1
461 α-MSH M0939 5443 POMC NP_001030333.1 P y n/d n/d
462 MSH6 M2445 2956 MSH6 NP_000170.1 P y y y
463 MSH6 M2820 2956 MSH6 NP_000170.1 P y y n/d
464 MSK-1 M5437 445349, 9252 RPS6KA5,Rps6ka5 ,NP_872198.1